Delhi High Court Grants Interim Protection to Vicky Ramancha in Ozempic Scam Case
The Delhi High Court has given interim relief to businessman Vicky Ramancha, the main accused in an alleged $18.8 million international scam involving fake doses of the anti-diabetic drug Ozempic.
On 19 August, Justice Neena Bansal Krishna directed that no coercive action be taken against Ramancha until the next hearing on 22 September. The Court, however, asked him to cooperate with the investigation and appear before the investigating officer on 25 August.
Earlier, the Patiala House Court had denied him anticipatory bail, citing the seriousness of the fraud and its impact on public health. Additional Sessions Judge Saurabh Laler stressed that India’s pharmaceutical sector is a “strategic national asset” and supplying counterfeit medicines posed grave risks to public safety and India’s global reputation as the “Pharmacy of the World.”
The lower court had noted that the case involved cross-border fraud and required detailed investigation. Following this, Ramancha approached the High Court.
The case began when US-based firm Assure Global LLC filed a complaint, accusing Ramancha of supplying spurious drugs to the US. It alleged that his Dubai-based company RNR Premier Medical Equipments Trading LLC and US-based RNR Global Procurement Corp had agreed to supply 1,25,000 doses of Ozempic.
Assure Global claimed it was misled with forged agreements and invoices, allegedly notarised in Delhi, and assurances of political influence. The firm paid $18.8 million, but the US FDA later seized the shipment, declaring the drugs counterfeit.
Based on court directions, the Delhi Police Economic Offences Wing (EOW) registered an FIR under IPC Sections 406 (criminal breach of trust), 420 (cheating), and 120B (criminal conspiracy).
